U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07313891) titled 'A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT' on Dec. 29, 2025.
Brief Summary: This is a Phase 3, open-label, randomized trial designed to evaluate the DFS of TURBT followed by NDV-1 (sustained-release gemcitabine-docetaxel) versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Study Start Date: May 01, 2026
Study Type: INTERVENTIONAL
Condition:
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Bladder (Urothelial, Transitional Cell) Cancer
Urothelial Carcinoma Bladder
Urologic Cancer
Inte...